主页 > 医学动态 >
【文摘发布】美国ERCP使用现状
Author: Simmons DT, Baron TH
Resource: Am J Gastroenterol. 2007 May;102(5):976-7
Abstract: Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the "magic bullet" continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication.
PMID: 17489783 Title: pERCePtions on ERCP utilization in the United States.
标题：美国应用ERCP的现状
Author: Simmons DT, Baron TH
Resource: Am J Gastroenterol. 2007 May;102(5):976-7
Abstract: Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the "magic bullet" continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication.
摘要：行ERCP后导致的急性胰腺炎仍是最致命的并发症。ERCP后导致胰腺炎的风险因素包括与患者、检查程序、操作者有关的因素。人们用很多方法试图发现理想的药剂来预防此并发症，但是几乎所有的药物评估都显示临床药效不足。这些药剂在早期单中心研究中显效，但随之的大规模多中心随机对照实验结果确令人失望。人们仍在寻找“魔法目标”，为避免这个并发症，最好的方法是选择合适的患者做CRCP及为高风险患者预防性安装管道支架。
PMID: 17489783 编译如下：[标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-27 11:48
医学,生命科学网